Comparison of the efficacy and safety indicators of DMARDs for rheumatoid arthritis: A network meta-analysis

OBJECTIVE: To compare efficacy and safety indicators of disease-modifying antirheumatic drugs, Sarilumab, Sirukumab, Baricitinib, Tocilizumab and Adalimumab in rheumatoid arthritis treatment by a network meta-analysis. METHODS: Medline, Embase, Web of Science, The Food and Drug Administration web si...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zunlian, Huang, Min, Yu, Bin, Huang, Yilan, Zheng, Silin, Yang, Xuping, Ning, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294891/
https://www.ncbi.nlm.nih.gov/pubmed/34398007
http://dx.doi.org/10.1097/MD.0000000000026524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294891/
https://www.ncbi.nlm.nih.gov/pubmed/34398007
http://dx.doi.org/10.1097/MD.0000000000026524

Ejemplares similares